Clinical trial
Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any…
NCT00219258 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00219258 |
|---|---|
| Title | Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma |
| Official title | A Randomized, Double-blind, Multi-centre Study to Evaluate the Fficacy and Safety of Zometa as a Treatment in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Treatment of Bone Metastases |
| Intervention type | Drug |
| Interventions | Zoledronic acid |
| Enrollment | 240 |
| Start date | Jul 1, 2005 |
| First posted | Sep 22, 2005 |
| Last update posted | Nov 23, 2009 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: